AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

AbbVie’s recently acquired Parkinson’s disease candidate tavapadon significantly reduced the burden of disease in a Phase III trial. The Phase III TEMPO-1 trial (NCT04201093) evaluated two ...

David Risinger’s rating is based on a thorough assessment of AbbVie’s recent clinical trial outcomes and the potential market for its Parkinson’s disease drug, tavapadon, along with an ...

On Thursday, Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon in Parkinson’s disease. The TEMPO-3 trial evaluated ...

Tavapadon met the primary endpoint in the pivotal Phase 3, TEMPO-1 fixed-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and ...

Patients showed a statistically significant improvement when two fixed doses of the drug, tavapadon, as a monotherapy were compared to placebo, as measured on a rating scale. The Movement Disorder ...

AbbVie ABBV announced positive top-line results from the pivotal phase III TEMPO-1 study which evaluated its recently acquired investigational drug tavapadon in adults with early Parkinson’s disease ...

Last week, AbbVie ABBV announced that a pivotal phase III study evaluating pipeline candidate tavapadon for treating early Parkinson's disease met the primary endpoint. The candidate was added to ...

The company's financial model was updated to include projections for tavapadon, a treatment under development that is anticipated to achieve peak sales of approximately $1 billion. This inclusion has ...

Emraclidine was part of AbbVie's acquisition of Cerevel last year, which also included Tavapadon, which reported positive Phase 3 data. Bristol's Cobenfy is now poised to dominate the ...

Tavapadon met the primary endpoint in the pivotal Phase 3, TEMPO-1 fixed-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and III ...